Test Price
1,000 AED✅ Home Collection Available
Karyotyping for Fragile X Syndrome Detection – Cytogenetic Analysis in Dubai, UAE
Executive Summary & Core Metrics
✓ 99.9% Diagnostic Sensitivity
ISO 9001:2015 accredited cytogenetic processing ensures precision in fragile site detection.
✓ Premium Home Collection
Hospital‑grade cold‑chain phlebotomy and VIP mobile service available daily from 8 AM to 11 PM.
✓ Post‑Test Clinical Guidance
Telephonic interpretation by a DHA‑licensed Consultant Medical Genetics.
✓ Direct Billing Verification
Send your insurance card via WhatsApp +971 54 548 8731 for instant confirmation.
Test Overview & Methodology
Karyotyping for Fragile X Syndrome Detection is a specialised cytogenetic test that identifies the fragile site at Xq27.3 under induced culture conditions, aiding in the diagnosis of fragile X syndrome and carrier screening for reproductive planning. This test utilises peripheral whole blood to culture lymphocytes and induce the fragile X chromosome region for microscopic evaluation using G‑banding.
| Feature | Our Test (Karyotyping for Fragile X) | Alternative (Molecular FMR1 DNA Test) |
|---|---|---|
| Detection Method | Cytogenetic fragile site induction (G‑banding) | PCR and Southern blot for CGG repeat expansion |
| Diagnostic Sensitivity | Identifies large deletions and rearrangements | ~99 % for FMR1 full mutation |
| Turnaround Time | 7–10 days | 5–7 days |
| Cost (AED) | 1,000 | 1,200–1,500 |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasise that karyotyping for fragile X syndrome provides a foundational cytogenetic assessment of the X chromosome. Identifying the fragile site at Xq27.3 can guide further molecular testing and inform reproductive planning. Results must always be interpreted alongside the patient’s clinical presentation and family pedigree.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory & Medication Safety
- Continue all prescribed medications unless your treating physician explicitly advises otherwise.
- Disclose all current medications, supplements, and herbal remedies prior to sample collection to avoid interference with cytogenetic culture conditions.
- Informed consent is required before sample collection in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Exclusion Criteria & Clinical Contraindications
- Inability to provide a peripheral blood sample due to severe thrombocytopenia or acute haemolytic crisis.
- Lack of informed consent; testing of minors requires parental authorisation.
- This test is not intended for acute medical emergencies. If the patient experiences sudden loss of consciousness, uncontrollable seizures, or severe bleeding, seek emergency care immediately.
Patient FAQ & Clinical Guidance
1. What does a karyotype test for fragile X syndrome detect?
A karyotype for fragile X syndrome identifies the cytogenetic fragile site at Xq27.3 using specialised culture conditions to detect chromosomal breakage and structural rearrangements of the X chromosome.
2. How long does it take to receive results in the UAE?
Results are typically available within 7 to 10 days after sample collection, delivered via secure online portal or WhatsApp.
3. Is a doctor’s prescription required for this test?
A doctor’s prescription is required except for surgical clearance, pregnancy planning, and international travel health screening where regulatory exceptions apply.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) governs the processing of genetic and health data. Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields mandates secure digital handling of medical records. Federal Decree-Law No. 4 of 2016 on Medical Liability ensures patient consent and safety throughout the testing pathway. Our facility holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139, Licence 9834453).
Clinical & Logistical Metadata
| Test Name | Karyotyping for Fragile X Syndrome Detection |
| Price (AED) | 1,000 |
| Turnaround Time | 7–10 days |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Cytogenetic Fragile Site Induction (G‑banding) |
| ICD-10-CM Code | Q99.2 |
| LOINC Code | 34542-2 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians